Everand Logo

Welcome to Everand!

  • STAT

    AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

    AstraZeneca attempts a recovery from a July failure with positive results from a new study, also in lung cancer, but aimed at a niche group of patients.
    by Adam Feuerstein Sep 08, 2017 2 minutes

    The jackpot cancer immunotherapy ambitions of AstraZeneca stumbled in July with the failure of a closely watched clinical trial in newly diagnosed lung cancer. Friday, the Anglo-Swedish drugmaker attempts a recovery with positive results from a new study, also in lung cancer, but aimed at a niche group of patients.

    AstraZeneca still trails cancer immunotherapy leaders Merck and

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min read
    STAT+: No, Alcohol Isn’t Good For You. Will New Dietary Guidelines Be Shaped More By Health Or Industry Interests?
    More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
    Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.

    Related